This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
The pH of your GI tract needs to be acidic for your medicine to dissolve and be absorbed. Proton pump inhibitors change the pH (acidity) in your GI tract.Also, your medicine may slow down how quickly your body processes pazopanib.
What might happen:
The amount of medicine in your blood may decrease and it may not work as well.If you medicine is absorbed, the amount of pazopanib in your blood may increase and cause more side effects than expected. Some expected side effects may be more severe than expected.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change your medicine or the timing of your cancer medicine.If you need to use an antacid while on pazopanib, take the antacid as far apart as possible from pazopanib.Let your doctor know right away if you experience nausea, vomiting, abdominal pain, yellowing of the eyes or skin, dark urine, itching, loss of appetite, any infections, unusual bleeding or bruising, chest or leg pain, numbness or weakness on one side or your body, trouble talking, severe headache, high blood pressure, shortness of breath, coughing, swelling of the ankles/legs, rapid/fast/irregular heartbeat, dizziness, or loss of consciousness.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Votrient (pazopanib) US prescribing information. GlaxoSmithKline August, 2020.
- 2.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 3.Abu Rmilah AA, Lin G, Begna KH, Friedman PA, Herrmann J. Risk of QTc Prolongation Among Cancer Patients Treated with Tyrosine Kinase Inhibitors. Int J Cancer. 2020 May 25.
- 4.USDepartment of Health and Human Services Food and Drug Administration. ICH E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available at: https://www.fda.gov/media/71372/download October, 2005.
- 5.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
- 6.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.